Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short term Debt: 2018-2023

Historic Short term Debt for Akebia Therapeutics (AKBA) over the last 2 years, with Dec 2023 value amounting to $17.5 million.

  • Akebia Therapeutics' Short term Debt fell 45.31% to $17.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $17.5 million, marking a year-over-year decrease of 45.31%. This contributed to the annual value of $17.5 million for FY2023, which is 45.31% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Short term Debt of $17.5 million as of Q4 2023, which was up 118.75% from $8.0 million recorded in Q3 2023.
  • Akebia Therapeutics' Short term Debt's 5-year high stood at $98.2 million during Q2 2022, with a 5-year trough of $8.0 million in Q3 2023.
  • For the 3-year period, Akebia Therapeutics' Short term Debt averaged around $51.7 million, with its median value being $32.0 million (2022).
  • Data for Akebia Therapeutics' Short term Debt shows a maximum YoY tumbled of 87.87% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Akebia Therapeutics' Short term Debt stood at $97.5 million in 2021, then plummeted by 67.19% to $32.0 million in 2022, then plummeted by 45.31% to $17.5 million in 2023.
  • Its last three reported values are $17.5 million in Q4 2023, $8.0 million for Q3 2023, and $24.0 million during Q2 2023.